Back grey_arrow_rt.gif
 
 
Nevirapine/Aptivus Expanded Access/Cost Program
 
 
  Boehringer Ingelheim Pharmaceuticals, Inc. is committed to making its HIV medications more accessible to patients in financial need. As part of this commitment, Boehringer Ingelheim has expanded its Virology Patient Assistance program (BI PAP) to allow more patients to qualify to receive Viramune®(nevirapine) tablets/oral suspension and Aptivus® (tipranavir) capsules/oral solution for free.
 
Patients now may qualify for the program if they are at or below 500 percent of the U.S. government's established poverty level, have no prescription drug coverage other than Medicare and spend at least three percent of their annual income on prescription drug costs in the current calendar year. Before Boehringer Ingelheim expanded the program, patients qualified if they were 300 percent or below poverty level. For more information on eligibility and to apply, patients in need should call 800-556-8317 or visit www.RxHope.com for information about the BI PAP. Information is also available at http://us.boehringer-ingelheim.com.
 
To further support access to APTIVUS and VIRAMUNE beyond its BI PAP, Boehringer Ingelheim is also working with Heinz-Welvista to create a partnership that will provide access to its HIV medicines for patients on ADAP waiting lists.
 
Please visit www.APTIVUS.com or www.VIRAMUNE.com for Full Prescribing Information, including Boxed Warnings
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org